Q2 FY27 press release: highest ever quarterly revenue and EBITDA reported
Rossari Biotech's Q2 FY27 release reports highest ever quarterly revenue of Rs. 697.6 crores, up 19.0% year-on-year, and highest ever EBITDA of Rs. 87.0 crores.
By ScoutQuest · · 2 min read
- Revenue
- Rs. 697.6 crores, up 19.0% year-on-year, highest ever quarterly revenue
- EBITDA
- Rs. 87.0 crores, highest ever EBITDA
- Profit after tax
- Rs. 38.9 crores, subdued due to higher depreciation from long-term projects
Rossari Biotech has released its press release for the quarter and half year ended September 30, 2026, reporting its highest ever quarterly revenue and EBITDA.
Q2 FY27, consolidated
- Revenue: Rs. 697.6 crores, a 19.0% growth year-on-year and the highest ever for a quarter
- EBITDA: Rs. 87.0 crores, also the highest ever for a quarter
- EBITDA margin: 12.5%
- Profit after tax: Rs. 38.9 crores; the company said it remained subdued due to higher depreciation arising from investments in long-term projects
H1 FY27, consolidated
- Total revenue: Rs. 1,394.8 crores
- EBITDA: Rs. 167.6 crores
- EBITDA margin: 12.0%
Balance sheet
- Net debt declined to Rs. 221 crores from Rs. 281 crores as of March 2026
Business updates
- The Board has approved the leasing of land by Rossari International Limited Company, a wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia
- Stage 1 EXCiPACT audit for the pharma business successfully completed
- One of India's largest EO storage facility commissioned at the Unitop site
- Textile specialty chemicals: new geographies Peru and Indonesia added, yarn and thread lubricants portfolio expanded, spin-finish for Fully Drawn Yarn introduced, and a new product category for denim processing
- Animal health and nutrition: new range of disinfectants, emulsifiers for poultry feed, liquid enzymes for exports and a biosurfactant based gut health modulator for poultry
What management said
- Growth was broad-based, led by healthy volume, improved product mix and focused execution across businesses
- The company continues to operate in an environment marked by raw material volatility, geopolitical uncertainty and cautious customer behaviour
- The agro business in general was sluggish because of El Niño
- Strategic initiatives include monetising non-core assets, rationalising lower-margin businesses and improving the product mix
Points a retail investor may track
- Progress on the Saudi greenfield facility after the Board's approval of the land lease
- Whether profit growth catches up with revenue growth as depreciation from long-term projects continues
- How the product mix and cost initiatives flow through to margins in the coming quarters
Also from Rossari Biotech
Earnings call: record quarterly revenue and EBITDA; Board approves land lease for Saudi greenfield plant
23 Oct 2026
Rossari Biotech files audio recording of Q2 & H1 FY27 earnings conference call held October 19, 2026
19 Oct 2026
Rossari Biotech reported strong quarter two earnings driven by higher exports and improved margins, even as the stock fell 3.5 percent despite the good numbers
19 Oct 2026
More numbers
- Q2 FY27 consolidated revenueRs. 697.6 crores
- Q2 FY27 revenue growth year-on-year19.0%
- Q2 FY27 EBITDARs. 87.0 crores
- Q2 FY27 EBITDA margin12.5%
- Q2 FY27 profit after taxRs. 38.9 crores
- H1 FY27 total revenueRs. 1,394.8 crores
- Net debt as of September 2026Rs. 221 crores
- Net debt as of March 2026Rs. 281 crores
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.